X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs GLENMARK PHARMA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD GLENMARK PHARMA WYETH LTD/
GLENMARK PHARMA
 
P/E (TTM) x 27.7 25.1 110.5% View Chart
P/BV x 5.3 3.9 136.2% View Chart
Dividend Yield % 1.3 0.3 414.3%  

Financials

 WYETH LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
GLENMARK PHARMA
Mar-17
WYETH LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044993 105.2%   
Low Rs818729 112.2%   
Sales per share (Unadj.) Rs298.6325.5 91.7%  
Earnings per share (Unadj.) Rs57.239.3 145.7%  
Cash flow per share (Unadj.) Rs58.448.7 120.0%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.80.2 786.1%  
Book value per share (Unadj.) Rs249.5159.2 156.7%  
Shares outstanding (eoy) m22.72282.17 8.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.6 117.9%   
Avg P/E ratio x16.321.9 74.2%  
P/CF ratio (eoy) x15.917.7 90.1%  
Price / Book Value ratio x3.75.4 69.0%  
Dividend payout %29.75.1 583.5%   
Avg Mkt Cap Rs m21,157242,991 8.7%   
No. of employees `0000.513.0 3.8%   
Total wages/salary Rs m40016,408 2.4%   
Avg. sales/employee Rs Th13,787.47,083.9 194.6%   
Avg. wages/employee Rs Th813.01,265.4 64.3%   
Avg. net profit/employee Rs Th2,643.3855.1 309.1%   
INCOME DATA
Net Sales Rs m6,78391,857 7.4%  
Other income Rs m353374 94.4%   
Total revenues Rs m7,13692,230 7.7%   
Gross profit Rs m1,61720,367 7.9%  
Depreciation Rs m272,644 1.0%   
Interest Rs m62,373 0.2%   
Profit before tax Rs m1,93815,724 12.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-5-810 0.6%   
Tax Rs m6323,827 16.5%   
Profit after tax Rs m1,30111,088 11.7%  
Gross profit margin %23.822.2 107.5%  
Effective tax rate %32.624.3 134.1%   
Net profit margin %19.212.1 158.8%  
BALANCE SHEET DATA
Current assets Rs m6,98468,746 10.2%   
Current liabilities Rs m2,05627,027 7.6%   
Net working cap to sales %72.645.4 160.0%  
Current ratio x3.42.5 133.5%  
Inventory Days Days9985 116.8%  
Debtors Days Days2496 25.1%  
Net fixed assets Rs m24424,132 1.0%   
Share capital Rs m227282 80.5%   
"Free" reserves Rs m5,44144,643 12.2%   
Net worth Rs m5,66844,925 12.6%   
Long term debt Rs m2545,363 0.1%   
Total assets Rs m7,901117,639 6.7%  
Interest coverage x353.37.6 4,633.5%   
Debt to equity ratio x01.0 0.4%  
Sales to assets ratio x0.90.8 110.0%   
Return on assets %16.511.4 144.5%  
Return on equity %22.924.7 93.0%  
Return on capital %34.019.1 177.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1556,152 0.0%   
Fx outflow Rs m2,6778,084 33.1%   
Net fx Rs m-2,66248,068 -5.5%   
CASH FLOW
From Operations Rs m9236,574 14.0%  
From Investments Rs m317-7,124 -4.4%  
From Financial Activity Rs m-4815,432 -8.9%  
Net Cashflow Rs m7591,992 38.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 7.2 34.4 20.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.5 289.5%  
Shareholders   21,978 56,727 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare WYETH LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS